The Food and Drug Administration (FDA) has expanded its approval of a ketamine nasal spray, Spravato (esketamine), as a standalone therapy for adults with treatment-resistant depression. Spravato was ...

强生(JNJ.US)1月21日宣布，美国FDA已批准其Spravato(esketamine)鼻喷雾剂用以治疗难治性抑郁症(TRD)成人患者。试验结果显示，Spravato在第4周时达到主要终点。

A nasal spray that contains esketamine — a potent derivative of ketamine — can now be taken on its own to treat adults with ...

We have made great strides in the medical community, with people having access to life-saving physical drugs as well as mental health medicine. A recent approval made by the FDA could be a great step ...

（原标题：FDA批准强生(JNJ.US)Spravato(esketamine)鼻喷雾剂用以治疗难治性抑郁症(TRD)成人患者） 智通财经APP获悉，强生(JNJ.US)1月21日宣布，美国FDA已批准 ...

The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in people who have not responded to at least two oral antidepressants.

Spravato is the brand name for esketamine, a chemical form of the ... Previous research cited by the FDA found that the nasal spray showed a "statistically significant effect" on severe depression ...

WEDNESDAY, Jan. 22, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major depressive disorder who have had an ...

Spravato is now the first stand-alone therapy for treatment-resistant depression, for patients who haven't responded to oral antidepressants.

an antidepressant nasal spray. The drug is now cleared for use as a standalone treatment for depression. Spravato is made from esketamine, one of two mirror-image molecules found in the anesthetic ...